News
Feed
Events
Feed
News
+ Events
Feed

CureVac

  • ISIN NL0015436031
  • Country Deutschland

Latest News

5 January 2024

13:00 Corporate

CureVac

Corporate

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

19 December 2023

15:23 Corporate

CureVac

Corporate

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

14 November 2023

13:00 Corporate

CureVac

Corporate

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

1 November 2023

13:00 Corporate

CureVac

Corporate

CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

28 September 2023

13:00 Corporate

CureVac

Corporate

CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany

12 September 2023

13:00 Corporate

CureVac

Corporate

CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage

17 August 2023

13:00 Corporate

CureVac

Corporate

CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update

1 August 2023

13:00 Corporate

CureVac

Corporate

CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK

14 July 2023

13:00 Corporate

CureVac

Corporate

CureVac Announces Update to the Management Team

13 July 2023

13:00 Corporate

CureVac

Corporate

CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights

20 June 2023

13:05 Corporate

CureVac

Corporate

CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

13:00 Corporate

CureVac

Corporate

CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board

19 June 2023

17:30 Corporate

CureVac

Corporate

CureVac Announces Voting Results of General Meeting

30 May 2023

13:00 Corporate

CureVac

Corporate

CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update

19 May 2023

13:00 Corporate

CureVac

Corporate

CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech

8 May 2023

13:00 Corporate

CureVac

Corporate

CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

25 April 2023

13:00 Corporate

CureVac

Corporate

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update

18 April 2023

13:00 Corporate

CureVac

Corporate

CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023

28 March 2023

22:05 Corporate

CureVac

Corporate

CureVac Announces Voting Results of Extraordinary General Meeting

10 February 2023

22:05 Corporate

CureVac

Corporate

CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares

8 February 2023

02:03 Corporate

CureVac

Corporate

CureVac Announces Pricing of Upsized Public Offering of Common Shares

6 February 2023

22:05 Corporate

CureVac

Corporate

CureVac Announces Proposed Public Offering of Common Shares

1 February 2023

13:00 Corporate

CureVac

Corporate

CureVac Welcomes Myriam Mendila as New Chief Development Officer

31 January 2023

14:12 Corporate

CureVac

Corporate

CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis®

30 January 2023

13:00 Corporate

CureVac

Corporate

CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs (news with additional features)

9 January 2023

13:00 Corporate

CureVac

Corporate

CureVac Appoints Alexander Zehnder as CEO From April 1, 2023

6 January 2023

13:00 Corporate

CureVac

Corporate

CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs

14 December 2022

22:05 Corporate

CureVac

Corporate

CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program

16 November 2022

13:00 Corporate

CureVac

Corporate

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update

11 November 2022

13:00 Corporate

CureVac

Corporate

CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

Upcoming Events

No Events found